508 related articles for article (PubMed ID: 12830003)
1. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
Alberts DS; Martínez ME; Hess LM; Einspahr JG; Green SB; Bhattacharyya AK; Guillen J; Krutzsch M; Batta AK; Salen G; Fales L; Koonce K; Parish D; Clouser M; Roe D; Lance P;
J Natl Cancer Inst; 2005 Jun; 97(11):846-53. PubMed ID: 15928305
[TBL] [Abstract][Full Text] [Related]
4. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
5. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
Poupon RE; Bonnand AM; Chrétien Y; Poupon R
Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
[TBL] [Abstract][Full Text] [Related]
6. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
8. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
10. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
[TBL] [Abstract][Full Text] [Related]
12. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
Batts KP; Jorgensen RA; Dickson ER; Lindor KD
Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
14. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
15. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
16. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.
Tomida S; Abei M; Yamaguchi T; Matsuzaki Y; Shoda J; Tanaka N; Osuga T
Hepatology; 1999 Jul; 30(1):6-13. PubMed ID: 10385632
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.
Papatheodoridis GV; Hadziyannis ES; Deutsch M; Hadziyannis SJ
Am J Gastroenterol; 2002 Aug; 97(8):2063-70. PubMed ID: 12190178
[TBL] [Abstract][Full Text] [Related]
18. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
19. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
[TBL] [Abstract][Full Text] [Related]
20. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
